REG - Genflow Biosciences - Genflow to Present at LLWC 2022

Genflow BiosciencesAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1340Ja&default-theme=true

RNS Number : 1340J  Genflow Biosciences PLC  25 April 2022

PRESS RELEASE

25 April 2022

 

Genflow Biosciences Plc

("Genflow" or "the Company")

 

Genflow to Present at Longevity Leaders 4(th) World Congress 2022

Genflow (LSE: GENF) is pleased to announce that Eric Leire, the Company's
Chief Executive Officer, will present an overview of the Company's
pre-clinical research into gene therapies to target the aging process at the
forthcoming Longevity Leaders World Congress ("LLWC"), 26-27 April 2022.

Mr Leire's presentation at the prestigious LLWC event will focus on the
potential of the Sirtuin-6 ("SIRT6") gene variant found in centenarians
(people aged more than 100 years old) to boost the development of anti-aging
therapies. The ability of SIRT6 to act on the rejuvenation of cells is a
significant finding, indicative of the SIRT6 gene mutation's potential to not
just halt the aging process, but to reverse it.

Genflow intends to promote healthy aging by delivering extra copies of SIRT6
into cells by using adeno-associated virus ("AAV") vectors as a safe and
efficient gene delivery system.

Genflow is a UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and diseases
associated with advanced age.  It is the first longevity biotechnology
company to list in Europe and seeks to be a reference company in the European
longevity sector.

 

 Title:               Could a Gene Variant Found in Centenarians Boost Efforts to Develop Anti-aging
                      Therapies?

 Day/Date:            Tuesday 26 April 2022

 Presentation Time:   14:55 - 15:30 BST

 

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com/)

 

 

 

 

 

 

 

-Ends-

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIIMTTMTATTMT